HC Wainwright Weighs in on Neurogene FY2027 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Neurogene in a report released on Thursday, March 26th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.93) for the year. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.08.

A number of other equities research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Lifesci Capital began coverage on shares of Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group assumed coverage on shares of Neurogene in a research report on Friday, February 27th. They set a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Neurogene currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Neurogene Trading Down 5.0%

Shares of NASDAQ NGNE opened at $20.35 on Friday. The firm has a market capitalization of $316.85 million, a PE ratio of -4.80 and a beta of 1.53. Neurogene has a 1 year low of $6.88 and a 1 year high of $37.27. The firm’s 50-day moving average is $19.52 and its 200-day moving average is $21.66.

Insider Activity

In other news, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares of the company’s stock, valued at $634,642.57. This represents a 18.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the completion of the sale, the chief financial officer owned 105,798 shares in the company, valued at $2,201,656.38. This represents a 3.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 11.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neurogene

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its holdings in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after buying an additional 1,232 shares during the period. Daiwa Securities Group Inc. acquired a new position in shares of Neurogene in the 4th quarter valued at $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after buying an additional 1,059 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Neurogene in the 4th quarter valued at $165,000. Institutional investors own 52.37% of the company’s stock.

Neurogene News Roundup

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $70 price objective for NGNE, providing bullish analyst support even as it modeled FY2027 EPS of ($4.93). This endorsement and high target can help underpin longer-term upside. HC Wainwright Buy/$70 Target
• Positive Sentiment: An MSN/aggregated report flagged a substantial analyst-driven price-target increase (reported as a 37.29% rise to 82.62), signaling at least one firm is materially more optimistic on Neurogene’s longer-term value — a clear positive for investor sentiment and potential catalyst for upside. Neurogene (NGNE) price target increased by 37.29% to 82.62
• Neutral Sentiment: A Globe and Mail roundup included Neurogene in a broader analysts-insights piece; such coverage can raise visibility but didn’t add new company-specific data likely to move the stock by itself. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Lifesci Capital cut Q1–Q4 2026 and FY2026 EPS estimates for NGNE across multiple notes, lowering FY2026 EPS to ($4.59) (from $4.33) while still keeping an “Outperform” rating and a $50 target. Those downward revisions to near-term profitability are a bearish driver and likely the primary reason for today’s weakness. Lifesci Capital EPS revisions / Outperform $50

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.